The Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved several diagnostic IHC antibodies with respective platforms, such as 22C3, 28-8, 73-10 from Dako (Agilent), SP142, SP263 from Ventana Medical Systems, to assess PD-L1 expression levels in patients with non-small cell lung cancer (NSCLC) [9, 13, 14]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.